Kornimate/medical-research-clean huggingface dataset:
clinical characteristics and outcome of patients with copd with pneumonia

Conditions: Pneumonia; Chronic Obstructive Pulmonary Disease

Summary: to identify the clinical characteristics of patients with chronic obstructive pulmonary disease (copd) combined with community-acquired pneumonia (cap) and the factors influencing clinical transition.

to identify the clinical characteristics of patients with chronic obstructive pulmonary disease (copd) combined with community-acquired pneumonia (cap) and the factors influencing clinical transition.compared to other chronic airway diseases, copd patients can often have cap in combination, but there is a lack of comparative studies between copd patients with cap and non-copd patients with cap.

Eligibility criteria:
inclusion criteria: 1. cap meets the diagnostic criteria published in 2016 chinese cap diagnosis and treatment guidelines; cpopd and aecopd meet the diagnostic criteria published in chinese 2013 copd diagnosis and treatment guidelines; 2. age ≧ 40years. exclusion criteria: 1. age \<40years; 2. pregnancy; 3. positive for human immunodeficiency virus (hiv) antibodies; 4. suspected or confirmed tuberculosis or fungal infection of the lung.
comparison of insulin glargine versus biphasic insulin aspart 30/70 or biphasic insulin aspart 30/70 in combination with metformin in subjects with type 2 diabetes.

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the aim of the trial is to compare the glycaemic control of insulin glargine versus biphasic insulin aspart 30/70 or biphasic insulin aspart 30/70 in combination with metformin in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * body mass index equal to or lesser than 35.0 kg/m2 * currently treated with oral hypoglycaemic drug exclusion criteria: * known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the investigator * any condition that the investigator and/or the sponsor feel would interfere with trial participation or evaluation of results
as-oct of the cornea in thyroid diseases

Conditions: Thyroid Eye Disease

Summary: use the anterior segment optical coherence tomography (as-oct) to evaluate the tear meniscus parameters, total corneal thickness (ct), and epithelial thickness in active and inactive thyroid eye diseases (ted) patients and compare them with age-matched controls.

a prospective case-control clinical study. the study subjects were divided into 3 groups, group 1 of inactive thyroid patients, group 2 of active thyroid patients, and group 3 of healthy controls. the as-oct was used to measure lower tear meniscus parameters (tear meniscus height (tmh), tear meniscus depth (tmd), and tear meniscus area (tma)), total ct and epithelial thickness

Eligibility criteria:
inclusion criteria: * the inclusion criteria were patients with thyroid disorders with age between 20 to 60 years with no ocular manifestations exclusion criteria: * being younger than 20 or older than 60, presence of systemic diseases as diabetes mellitus (dm) and autoimmune diseases as rheumatoid arthritis (ra) that may cause dry eye, previous ocular surgery, use of contact lenses, smokers, pregnant women, and breastfeeding women.

Keywords: cornea- tear film- as-oct
study of zg005 in combination with gecacitinib in patients with relapsed or refractory lymphoma

Conditions: Lymphoma

Summary: part 1: 1. to explore the safety of zg005 in combination with gecacitinib in patients with relapsed or refractory lymphoma. 2. to determine the recommended phase ii dosing regimen for relapsed or refractory lymphoma. part 2: to evaluate the efficacy of zg005 in combination with gecacitinib in patients with relapsed or refractory lymphoma.


Eligibility criteria:
inclusion criteria: * fully understand this study and voluntarily sign the icf； * age ≥18 at icf signing, regardless of gender； * histologically confirmed relapsed or refractory lymphoma. exclusion criteria: * lymphoma with known cns involvement； * severe cardiovascular/cerebrovascular diseases. * any other reason deeming the participant unsuitable for the study, as judged by the investigator.
effectiveness of ellasi intervention towards polytrauma patients in the emergency department

Conditions: Polytrauma

Summary: this clinical trial aims to test the effectiveness of ellasi intervention in response time, deterioration score, and metabolic status of polytrauma patients in the emergency department. the main questions it aims to answer are: 1. is the response time of polytrauma patients who receive ellasi in the intervention group faster than the control group? 2. is the deterioration score of polytrauma patients who receive ellasi in the intervention group better than the control group? 3. is the metabolic status of polytrauma patients who receive ellasi in the intervention group better than the control group? polytrauma patients in the intervention group will receive ellasi, a structured intervention consisting of the six following: 1. evaluation of airway and cervical control, remove the foreign body, fluid, etc., from the airway, 2. patient positioning and giving oxygen, head-up, 3. stabilisation, including iv insertion, applying pressure and bandage, place monitor, and haemodynamic monitoring 4. assessment: re-assessment of pain and other main complaints 5. make sure informed consents are documented 6. inform patient and family for further intervention polytrauma patients in the control group will receive the usual/standard intervention. response time, early warning score, and arterial blood gas of polytrauma patients from both groups will be obtained and documented before and after the intervention.


Eligibility criteria:
inclusion criteria: * polytrauma patients * have not received medical treatment before exclusion criteria: * canceled registration * polytrauma patients who are unwilling to participate in the study
evaluation of the prophylactic efficacy of tdcs in chronic migraine

Conditions: Chronic Migraine as Defined by Criteria of International Headache Society (IHS)

Summary: the purpose of this study is to determine whether tdcs is an effective prophylactic therapy of chronic migraine.

consenting patients will report on a book, all of their migraine attack for 1 month. then they will be randomized to the active tdcs group or sham tdcs group. patients will have one session of tdcs per day during the first week, then one session per week for a month and finally a session every 15 days for 1 month. after tdcs sessions, patients will be followed for 3 months. throughout their participation in the study, patients will complete their migraine record (1month of base line before tdcs, 2 months during tdcs, 3 months after tdcs). patients will have 5 evaluation examinations: * the first, one before tdcs, * the second, 1 month after the beginning of tdcs * the third, immediately after the end of tdcs * the fourth, 1 month after the end of tdcs * and the last one, 3 months after the end of tdcs. the physician responsible for conducting tdcs sessions will make the randomization via a website. the physician in charge of the evaluation examinations will don't know the allocated treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic migraine for more than 1 year * stable treatment since 1 month * frequency of migraine crisis is above 8 per month during last month * chronic migraine that has not been improved over the previous year by at least 3 different prophylactic treatments recommended and well conducted * patient agreeing not to try other migraine prophylactic treatment, throughout the study * patient's written consent exclusion criteria: * history of drug addiction, epilepsy, or severe head trauma with bone break * history of psychiatric illness (psychosis and severe cognitive disorders) may interfere with the proper conduct of the study * presence of intracranial ferromagnetic material or an implanted stimulator * introduction of a new treatment for less than a month * pregnant women, parturient women, breast-feeding mother. lack of effective contraception * person not understanding the study protocol

Keywords: chronic migraine, tdcs, transcranial direct current stimulation
study to evaluate the safety and efficacy of topical minocycline fxfm244 in impetigo patients

Conditions: Impetigo

Summary: impetigo is a common, highly infectious skin disease caused by bacterial infection and characterized by crusting skin lesions. it is most common in children, particularly children in unhealthy living conditions. in adults, it may follow other skin disorders. impetigo is caused primarily by the bacteria streptococcus pyogenes and/or staphylococcus aureus, which can also be isolated from impetigo lesions. this is a pilot phase ii study to evaluate the tolerability and safety and to monitor the clinical efficacy of topical minocycline foam fxfm244 in impetigo patients.

a randomized, parallel-group, double (investigator, patient) blind, comparative dose range finding clinical trial. the study will involve two treatment groups. eligible patients will be randomized to receive either fxfm244 - 1%, fxfm244 - 4% , in a blinded fashion. patients will be treated twice daily for 7 days. following the screening period and baseline visit, study subjects will return at days 3, 7 and 14. at each visit, patients will be evaluated via lesion count, global assessment tolerability and safety.

Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo * patients 2 years of age or older, and in general good health * patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm. * no known medical conditions that, in the investigator's opinion could interfere with study participation * patient / patient's guardian (in the case of children) willing and able to comply with all requirement of the protocol * patient / patient's guardian willing and able to give written informed consent prior to participation in the study exclusion criteria: * presence of skin diseases at or near the investigational area * immunosuppressed state or other serious systemic disease * signs and/or symptoms of systemic infection * presence of skin infection/disorder not amenable to topical antibacterial treatment only * presence of secondarily-infected animal/human bite * presence of secondarily infected burn wound * topical or systemic use of medicinal or other products before or during the study (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators); or other drugs, which in the investigators opinion could confound the evaluation of the effect of the study drugs * known or suspected hypersensitivity to minocycline or any of the excipients in the study medication * participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomization * patients previously enrolled/randomized in this study * use of another investigational drug within 30 days prior to entry into this study. * pregnant or lactating women.

Keywords: topical minocycline foam phase ii impetigo
viviant 20mg special investigation (regulatory post marketing commitment plan)

Conditions: Osteoporosis

Summary: in this survey, to collect the safety and efficacy information of bazedoxifene in daily medical practice will be examined. in addition, the necessity of special investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.

all the subjects whom an investigator prescribes the first bazedoxifene (viviant) tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * post menopausal women subjects with osteoporosis who has no experience of use of bazedoxifene. exclusion criteria: * subject with present or past venous thromboembolism such as deep venous thrombosis, pulmonary embolism, or retinal venous thrombosis * subject in long-term immovability (postoperative recovery, long-term bed rest) * subject with antiphospholipid antibody syndrome

Keywords: osteoporosis post menopausal women serm japanese viviant regulatory post marketing commitment plan long term treatment
a trial to investigate the efficacy, pharmacokinetics, safety and tolerability of biochaperone insulin lispro in comparison to humalog® u-100 in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: this is a double-blind, randomised, controlled, two-period crossover phase ib trial using an individualised standard meal with a fixed nutrient ratio in subjects with type 2 diabetes mellitus to investigate post-prandial blood glucose control with biochaperone insulin lispro compared to insulin lispro (humalog®, eli lilly and company) before and after a period of multiple daily dose administrations for 14 days. each subject will be randomised to a sequence of two treatments, either biochaperone insulin lispro-humalog® or humalog®-biochaperone insulin lispro. injections will take place immediately before an individualised standard meal in the morning of day 1, 2, 13, and 14. insulin doses will be determined at the screening visit. during the outpatient phase the subjects will keep their basal insulin constant (except changes for safety reason). they will self-measure blood glucose at least 4 times daily (pre-prandial and at bedtime). in addition, on two days per outpatient period (day 5 and 9) blood glucose will be measured 7 times daily (pre-prandial, 2 hours post-prandial and at bedtime).


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus ≥ 12 months * treated with stable multiple daily insulin ≥ 3 months (basal-bolus therapy or only bolus insulin therapy) * current total daily insulin treatment \<1.2 (i)u/kg/day * body mass index below or equal to 40.0 kg/m² * hba1c ≤ 9.0% by local laboratory analysis exclusion criteria: * known or suspected hypersensitivity to trial products or related products * type 1 diabetes mellitus * previous participation in this trial * the receipt of any investigational product within 60 days prior to this trial * clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the investigator considering the underlying disease * presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the investigator * presence of renal impairment (estimated glomerular filtration rate (egfr)\<60 milliliters/minute/1.73m²) * presence of late diabetic complications and/or acute coronary heart disease. * known slowing of gastric emptying and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption * unusual meal habits and special diet requirements or unwillingness to eat the food provided in the trial * current treatment with corticosteroids
speed of processing (sop) training plus α-tacs

Conditions: Cognitive Dysfunction; Mild Cognitive Impairment; tACS; Cognitive Training

Summary: the current proposal aims to assess if the combination of speed of processing (sop) training with alpha tacs (α-tacs) is able to increase brain speed of processing as assessed by the useful field of view (ufov) when comparing to sop training plus sham α-tacs. moreover, a second aim is to assess if those changes in speed of processing transfer to other cognitive domains, such as memory, language and executive functioning. furthermore, the mechanisms underlying these interventions will be tested, namely to assess brain connectivity and coherence as assessed by eeg. to that purpose, the aim of the current proposal is to conduct a double-blind, parallel randomized trial assessing the effects of combining sop with alpha endogenous tacs (either active or sham) in participants with mild cognitive impairment (mci).

dementia is thought to affect 6.3 million people across europe and is especially prevalent in people over 85 years old (23.7%). in this sense, several cognitive training programs, alone or in combination with non-invasive brain stimulation have been used in order to ameliorate age-related cognitive impairments, and even to act in a prophylactic manner in order to prevent more extreme deficits, such as the ones presented in mild cognitive impairment, or even dementia. despite all these efforts, the effects of ct - combined or not - with several forms of non-invasive brain stimulation have been modest at most. the current proposal aims to assess if speed of processing (sop) training combined with alpha tacs (α-tacs) increases speed of processing as assessed by the useful field of view (ufov) when comparing to sop training and sham α-tacs. furthermore, association betweens changes in speed of processing and changes in other cognitive domains, such as memory, language and executive functioning will be assessed. finnaly, the current proposal aims at probing the mechanisms underlying these interventions, namely to test brain connectivity and coherence as assessed by eeg.

Eligibility criteria:
inclusion criteria: * community-dwelling adults aged 65 years and older, with cognitive complains in memory or other functions, which have declined over time exclusion criteria: * score in the mini mental examination less than 23 (or over 28); * diagnosis of alzheimer´s disease, any other medical condition that may predispose participants for a forthcoming decline in function, or that may increase their risk of mortality during the duration of the study. * any contra-indication to tacs, severe sensory losses or communication difficulties that will prevent them from successfully complete the training. * had any cognitive training in the past.

Keywords: mci tacs cognitive training
specialty mental health probation in north carolina

Conditions: Mental Illness; Substance Use; Criminal Behavior

Summary: specialty mental health probation for offenders with severe mental illness has been widely disseminated; however, randomized studies are needed to determine its effectiveness. the purpose of the study is to test the feasibility and efficacy of specialty mental health probation (smhp) for probationers with mental illness in north carolina. 320 adult probationers with mental illness in will be randomly assigned to specialty mental health probation (experimental condition) or usual probation (control condition). probationers assigned to the experimental condition will be supervised by specialty mental health probation officers, who will have reduced caseloads and advanced training in mental health and other topics. probationers assigned to the control condition will receive standard probation. criminal justice and mental health outcomes will be examined.

specialty mental health probation for offenders with severe mental illness has been widely disseminated; however, randomized studies are needed to determine its effectiveness. the purpose of the study is to test the feasibility and efficacy of specialty mental health probation (smhp) for probationers with mental illness in north carolina. 320 adult probationers with severe mental illness in will be randomly assigned to receive specialty mental health probation (experimental condition) or standard probation (control condition). probationers assigned to the experimental condition will be supervised by specialty mental health probation officers, who will have reduced caseloads and advanced training in mental health and other topics. probationers assigned to the control condition will receive standard probation. criminal justice and mental health outcomes will be examined.

Eligibility criteria:
inclusion criteria: * qualifying diagnosis of severe mental illness - schizophrenia, bipolar disorder, major depression, post-traumatic stress disorder + on probation in north carolina + capable of passing study competency quiz administered by the research team exclusion criteria: * none
bnp, serum troponin and d-dimer as risk factors in patients with covid-19

Conditions: COVID-19

Summary: to evaluate the role of n terminal pro b type natriuretic peptide (ntprobnp), d-dimer, and troponin - i as risk factors in covid-19 patients and to correlate these markers with in-hospital death in patients with covid-19

coronavirus disease-2019 (covid-19), a contagious novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (sars-cov-2; formerly called 2019-ncov). cardiac injury is a common condition among the hospitalized patients with covid-19. it t was recently reported that 19.7% patients with covid-19 had cardiac injury with more adverse clinical outcomes compared to those without cardiac injury (shi s, et al, 2020) fulminant myocarditis due to direct viral infection can certainly occur, but in patients with increased oxygen demands due to tachycardia and fever and reduced oxygen delivery due to hypotension and hypoxemia, covid 19 disease can cause myocardial injury indirectly. cytokines released during the acute infection can elicit activation of cells within pre-existing atherosclerotic lesions, augmenting thrombotic risk and risk of ischemic syndromes. moreover, microvascular activation by cytokines can cause not only myocardial injury but can also harm other organ systems commonly involved in covid-19 infections including the kidneys.(peter,2020) treatment in intensive care units (icu) has become a major challenge; therefore, early recognition of severe forms is absolutely essential for timely triaging of patients. several laboratory parameters may facilitate the assessment of disease severity. the recognized risk factors such as old age and underlying comorbidities-particularly cardiovascular diseases, diabetes, respiratory diseases, and other conditions (zhou et al,2020) several markers have been identified that modulate the course of covid-19. the heart failure marker, n terminal pro b type natriuretic peptide (nt-probnp), increased significantly during the course of hospitalization (guo t, et al ,2020) the sensitivity of cardiac troponin testing that ensures it is one of the earliest and most precise indicators of end organ dysfunction. cardiac troponin testing could prompt early initiation of measures to improve tissue oxygenation and perfusion. covid-19 infection is associated with intra-alveolar fibrin deposition, leading to lethal respiratory failure; reports suggesting that anticoagulation or fibrinolytic therapy can improve clinical outcomes (wang j, et al , 2020) ; case series implying that large percentages of severely affected covid-19 patients suffer clinically significant thrombosis (porfidia a , et al ,2020)

Eligibility criteria:
inclusion criteria: * patients with covid-19 (moderate and severe cases) different age groups exclusion criteria: * patients who had stroke and acute myocardial infarction, malignant tumor, and pregnancy.